NCT03077477 - Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers | Biotech Hunter

Timeline

Start Date

June 12, 2018

Primary Completion Date

June 12, 2018

Study Completion Date

June 12, 2018

Conditions

NeoplasmsMedication ToxicityTolerance

Interventions

DRUG

AMXT 1501

Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.

DRUG

Placebo Oral Tablet

"Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered"

Trial Locations (1)

66211

IQVIA (formerly Quintiles IMS), Overland Park